408 related articles for article (PubMed ID: 36969219)
1. Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer.
Cui H; Ren X; Dai L; Chang L; Liu D; Zhai Z; Kang H; Ma X
Front Immunol; 2023; 14():1145552. PubMed ID: 36969219
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
4. A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses.
Li J; Qiao H; Wu F; Sun S; Feng C; Li C; Yan W; Lv W; Wu H; Liu M; Chen X; Liu X; Wang W; Cai Y; Zhang Y; Zhou Z; Zhang Y; Zhang S
Front Immunol; 2022; 13():998140. PubMed ID: 36275774
[TBL] [Abstract][Full Text] [Related]
5. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment-based clusters in predicting prognosis and guiding immunotherapy in breast cancer.
Liu Y; He X; Yang YI
J Biosci; 2024; 49():. PubMed ID: 38287674
[TBL] [Abstract][Full Text] [Related]
7. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
Wang Z; Liu H; Gong Y; Cheng Y
Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
[TBL] [Abstract][Full Text] [Related]
8. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
9. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
Yu Z; Zhu Y; Ji J
Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
11. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
12. Identification of CD4
Ning S; Wu J; Pan Y; Qiao K; Li L; Huang Q
Front Immunol; 2022; 13():880769. PubMed ID: 35603183
[TBL] [Abstract][Full Text] [Related]
13. A tumor microenvironment-related risk model for predicting the prognosis and tumor immunity of breast cancer patients.
Geng S; Fu Y; Fu S; Wu K
Front Immunol; 2022; 13():927565. PubMed ID: 36059555
[TBL] [Abstract][Full Text] [Related]
14. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer.
Liang J; Wang X; Yang J; Sun P; Sun J; Cheng S; Liu J; Ren Z; Ren M
Front Immunol; 2023; 14():1198826. PubMed ID: 38035071
[TBL] [Abstract][Full Text] [Related]
15. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel prognostic signature based on single-cell combined bulk RNA analysis in breast cancer.
Xiao Y; Hu G; Xie N; Yin L; Pan Y; Liu C; Lou S; Zhu C
J Gene Med; 2024 Feb; 26(2):e3673. PubMed ID: 38404059
[TBL] [Abstract][Full Text] [Related]
17. Unfolded protein response signature unveils novel insights into breast cancer prognosis and tumor microenvironment.
Zhou N; Kong D; Lin Q; Yang X; Zhou D; Lou L; Huang F
Cancer Genet; 2023 Aug; 276-277():17-29. PubMed ID: 37343507
[TBL] [Abstract][Full Text] [Related]
18. Identification of a pyroptosis-related prognostic signature in breast cancer.
Chen H; Luo H; Wang J; Li J; Jiang Y
BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
[TBL] [Abstract][Full Text] [Related]
19. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
Front Oncol; 2022; 12():915662. PubMed ID: 36033441
[TBL] [Abstract][Full Text] [Related]
20. Exploration of prognosis and immunometabolism landscapes in ER+ breast cancer based on a novel lipid metabolism-related signature.
Shen L; Huang H; Li J; Chen W; Yao Y; Hu J; Zhou J; Huang F; Ni C
Front Immunol; 2023; 14():1199465. PubMed ID: 37469520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
